Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Mar;45(3):981-5.
doi: 10.1128/AAC.45.3.981-985.2001.

Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy

M A Boogaerts  1 , J Maertens, R Van Der Geest, A Bosly, J M Michaux, A Van Hoof, M Cleeren, R Wostenborghs, K De Beule
Affiliations
Clinical Trial

Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy

M A Boogaerts et al. Antimicrob Agents Chemother. 2001 Mar.

Abstract

The pharmacokinetics and safety of an intravenous hydroxypropyl-beta-cyclodextrin solution of itraconazole administered for 7 days followed by itraconazole oral solution administered at 200 mg once or twice daily for 14 days were assessed in 17 patients with hematologic malignancies. Steady-state plasma itraconazole concentrations were reached by 48 h after the start of intravenous treatment. The mean trough plasma itraconazole concentration at the end of the intravenous treatment was 0.54 +/- 0.20 microg/ml. This concentration was not maintained during once-daily oral treatment but increased further in the twice-daily treatment group, with a trough itraconazole concentration of 1.12 +/- 0.73 microg/ml at the end of oral treatment. As expected in the patient population studied, all patients experienced some adverse events (mainly gastrointestinal). Biochemical and hematologic abnormalities were frequent, but no consistent changes occurred. In conclusion, 7 days of intravenous treatment followed by 14 days of twice-daily oral treatment with itraconazole solution enables plasma itraconazole concentrations of at least 0.5 microg/ml to be reached rapidly and to be maintained. The regimen is well tolerated and has a good safety profile.

PubMed Disclaimer

References

    1. Barone J A, Moskovitz B L, Guarnieri J, Hassell A E. Enhanced bioavailability of itraconazole solution compared with capsules in healthy volunteers. Pharmacotherapy. 1997;17:194–195.
    1. Barone J A, Moskovitz B L, Guarnieri J, Hassell A E, Colaizzi J L, Bierman R H, Jessen L. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy. 1998;18:295–301. - PubMed
    1. Boogaerts M, Garber G, Winston D, Reboli A, Schwarer A, Bow E, Peeters M, Materman E, De Beule K. Itraconazole (IT) compared with amphotericin B (AMB) as empirical therapy for persistent fever of unknown origin (FUO) in neutropenic patients (PTS) Bone Marrow Transplant. 1999;23(Suppl. 1):S111.
    1. Boogaerts M A, Verhoef G E, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses. 1989;32(Suppl. 1):103–108. - PubMed
    1. Cartledge J D, Midgely J, Gazzard B G. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol. 1997;50:477–480. - PMC - PubMed

Publication types